Acupuncture and sham acupuncture appear equally effective in treating migraines, according to a clinical trial published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.
An international team of researchers conducted a randomized controlled trial to determine the effect of acupuncture compared with sham acupuncture in treating migraines in 480 patients at nine hospitals in China. The patients were randomly assigned to four groups, including one sham acupuncture group and three groups receiving different types of acupuncture. Patients were aged 18 to 65 years and were eligible if they had experienced migraines for more than one year, with two to three attacks in the three months preceding the study period.
Migraines affect about 6%-8% of men and 16%-18% of women in the US and England. Acupuncture is used to treat migraines, but evidence is mixed on its effectiveness in treating the condition and whether it is the placebo effect rather than a therapeutic effect that alleviates symptoms. Acupuncture distinguishes between real acupuncture points and nonacupuncture (or sham) points.
"We found that the outcomes following acupuncture were significantly better than with sham acupuncture during weeks 13-16, but the effect was clinically minor," writes Dr. Fan-rong Liang, Chengdu University of Traditional Chinese Medicine, Chengdu, China, with coauthors.
About half to three-quarters of people with migraines were better after acupuncture and sham acupuncture after 16 weeks. "Acupuncture has a large effect on treating migraines, but the specific therapeutic effect may be minor," state the authors.
In related commentary http://www.
In a second randomized controlled trial http://www.
In the Netherlands, a substantial number of people with migraines use too much medication for migraine attacks, whereas only 8%-12% of all migraine patients use prophylaxis. Although the approach resulted in more people taking prescription medication to prevent migraines, no clinically relevant effect was seen after six months.
"We found no clinically relevant effect of a proactive approach to migraine in primary care for patients who were using two or more doses of triptan per month," writes Dr. Antonia Smelt, Leiden University Medical Centre, Leiden, the Netherlands, with coauthors.
"It is possible that the intervention resulted in better treatment for patients not using prophylactic medication at baseline who had two or more attacks of migraine per month. Future interventions in primary care should target these patients," the authors conclude.